Search

Your search keyword '"Legros, L"' showing total 384 results

Search Constraints

Start Over You searched for: Author "Legros, L" Remove constraint Author: "Legros, L"
384 results on '"Legros, L"'

Search Results

1. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

2. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

3. Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study

5. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

11. Toxic iron species in lower-risk myelodysplastic syndrome patients : course of disease and effects on outcome

12. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

13. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

14. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.

18. HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INDUCES DURABLE REMISSIONS IN PATIENTS WITH POEMS SYNDROME: A RETROSPECTIVE STUDY OF THE PLASMA CELL DISORDERS SUBCOMMITTEE OF THE CHRONIC MALIGNANCY WORKING PARTY OF THE EBMT: PH-O134

21. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

29. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

30. Guide pratique de suivi du transplanté hépatique

34. Erratum to: High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

41. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

42. Results of a Phase II Study of Guadecitabine in Higher Risk MDS Patients Refractory to or Relapsing after Azacitidine Treatment

43. A Retrospective Validation of International Consortium for MDS/MPN Response Criteria in CMML Treated with Hypomethylating Agents

44. Baseline serum ferritin is an independent predictive factor of mortality in patients with chronic hepatitis C after long term follow-up

46. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

48. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias

50. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Catalog

Books, media, physical & digital resources